Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1988 1
1989 4
1990 8
1991 6
1992 8
1993 4
1994 10
1995 4
1996 7
1997 5
1998 6
1999 6
2000 5
2001 7
2002 8
2003 6
2004 4
2005 3
2006 2
2007 4
2008 7
2009 4
2010 1
2012 1
2014 1
2015 1
2017 1
2021 1
2023 0

Text availability

Article attribute

Article type

Publication date

Search Results

123 results

Results by year

Filters applied: . Clear all
Page 1
Quinaprilat: a review of its pharmacokinetics, pharmacodynamics, toxicological data and clinical application.
Kieback AG, Felix SB, Reffelmann T. Kieback AG, et al. Expert Opin Drug Metab Toxicol. 2009 Oct;5(10):1337-47. doi: 10.1517/17425250903282773. Expert Opin Drug Metab Toxicol. 2009. PMID: 19761414 Review.
Quinaprilat is excreted mainly in urine. In long-term animal studies, quinaprilat was not teratogenic, mutagenic or carcinogenic. ...CONCLUSION: Quinaprilat is an attractive ACE inhibitor, which potently inhibits tissue ACE....
Quinaprilat is excreted mainly in urine. In long-term animal studies, quinaprilat was not teratogenic, mutagenic or carcinogen …
Quinaprilat during cardioplegic arrest in the rabbit to prevent ischemia-reperfusion injury.
Korn P, Kröner A, Schirnhofer J, Hallström S, Bernecker O, Mallinger R, Franz M, Gasser H, Wolner E, Podesser BK. Korn P, et al. J Thorac Cardiovasc Surg. 2002 Aug;124(2):352-60. doi: 10.1067/mtc.2002.121676. J Thorac Cardiovasc Surg. 2002. PMID: 12167796 Free article. Clinical Trial.
When administered during ischemia, quinaprilat significantly improved recovery of coronary flow (70% +/- 8%, P =.028 vs quinaprilat during reperfusion [49% +/- 5%] and P =.023 vs control [48% +/- 6%]). l-Arginine (55% +/- 7%) showed no significant effect. ...Ultrast …
When administered during ischemia, quinaprilat significantly improved recovery of coronary flow (70% +/- 8%, P =.028 vs quinaprila …
A pharmacodynamic and pharmacokinetic comparison of intravenous quinaprilat and oral quinapril.
Breslin E, Posvar E, Neub M, Trenk D, Jahnchen E. Breslin E, et al. J Clin Pharmacol. 1996 May;36(5):414-21. doi: 10.1002/j.1552-4604.1996.tb05028.x. J Clin Pharmacol. 1996. PMID: 8739020 Clinical Trial.
The magnitude of effect was similar after administration of 20 mg quinapril orally and 10 mg quinaprilat intravenously. Duration of action was longer, however, after administration of intravenous quinaprilat (10 mg) than after oral quinapril (20 mg), due to the high …
The magnitude of effect was similar after administration of 20 mg quinapril orally and 10 mg quinaprilat intravenously. Duration of a …
The pharmacokinetics and pharmacodynamics of quinapril and quinaprilat in renal impairment.
Begg EJ, Robson RA, Bailey RR, Lynn KL, Frank GJ, Olson SC. Begg EJ, et al. Br J Clin Pharmacol. 1990 Aug;30(2):213-20. doi: 10.1111/j.1365-2125.1990.tb03767.x. Br J Clin Pharmacol. 1990. PMID: 2144994 Free PMC article.
The apparent oral plasma clearance of quinaprilat (dose of quinapril equivalent/AUC of quinaprilat) was directly related to creatinine clearance (CLCr). ...Peak and trough concentrations of quinaprilat, and its apparent elimination half-life, varied inversely …
The apparent oral plasma clearance of quinaprilat (dose of quinapril equivalent/AUC of quinaprilat) was directly related to cr …
Pharmacokinetics of quinapril and its active metabolite, quinaprilat, in patients on chronic hemodialysis.
Blum RA, Olson SC, Kohli RK, Horvath AM, Sedman AJ, Posvar EL. Blum RA, et al. J Clin Pharmacol. 1990 Oct;30(10):938-42. doi: 10.1002/j.1552-4604.1990.tb03574.x. J Clin Pharmacol. 1990. PMID: 2229454
Quinapril was extensively de-esterified to its diacid metabolite, quinaprilat. Mean tmax and Cmax for quinaprilat were 4.5 hours and 671 ng/mL, respectively. Mean apparent plasma clearance for quinaprilat was 24.0 mL/min with a mean half-life of 17.5 hours. A …
Quinapril was extensively de-esterified to its diacid metabolite, quinaprilat. Mean tmax and Cmax for quinaprilat were 4.5 hou …
Disposition of quinapril and quinaprilat in the isolated perfused rat kidney.
Kugler AR, Olson SC, Smith DE. Kugler AR, et al. J Pharmacokinet Biopharm. 1995 Jun;23(3):287-305. doi: 10.1007/BF02354286. J Pharmacokinet Biopharm. 1995. PMID: 8834197 Free article.
An isolated perfused rat kidney model was used to probe the renal disposition of quinapril and quinaprilat after separate administration of each drug species. Control studies were performed with drug-free perfusate (n = 8) and perfusate containing quinapril (n = 9) or q …
An isolated perfused rat kidney model was used to probe the renal disposition of quinapril and quinaprilat after separate administrat …
Protective effect of quinaprilat, an active metabolite of quinapril, on Ca2+-overload induced by lysophosphatidylcholine in isolated rat cardiomyocytes.
Ma H, Hashizume H, Hara A, Yazawa K, Abiko Y. Ma H, et al. Jpn J Pharmacol. 1999 Jan;79(1):17-24. doi: 10.1254/jjp.79.17. Jpn J Pharmacol. 1999. PMID: 10082313 Free article.
Since quinaprilat has an inhibitory action on ACE and quinapril has practically no inhibitory action on ACE, it is likely that the inhibitory action of quinaprilat on ACE is necessary for the protective effect of the drug against LPC-induced changes. ...We conclude …
Since quinaprilat has an inhibitory action on ACE and quinapril has practically no inhibitory action on ACE, it is likely that the in …
Quinaprilat induces arterial vasodilation mediated by nitric oxide in humans.
Haefeli WE, Linder L, Lüscher TF. Haefeli WE, et al. Hypertension. 1997 Oct;30(4):912-7. doi: 10.1161/01.hyp.30.4.912. Hypertension. 1997. PMID: 9336392
In particular, recently developed ACE inhibitors with tissue-penetrating properties, such as quinaprilat, may exert vascular effects via the bradykinin B2-receptor. ...The response to bradykinin was augmented by both ACE inhibitors, but the effect of quinaprilat (3. …
In particular, recently developed ACE inhibitors with tissue-penetrating properties, such as quinaprilat, may exert vascular effects …
Reabsorption and metabolism of quinapril and quinaprilat in rat kidney: in vivo micropuncture studies.
Smith DE, Kugler AR, Schnermann JB. Smith DE, et al. J Pharm Sci. 1995 Oct;84(10):1147-50. doi: 10.1002/jps.2600841002. J Pharm Sci. 1995. PMID: 8801325
The tubular uptake and esterolysis of quinapril and quinaprilat were studied in male Sprague-Dawley rats using an in vivo micropuncture technique. [3H]Quinapril or [3H]quinaprilat was injected with [14C]inulin into either proximal or distal segments of the renal tub …
The tubular uptake and esterolysis of quinapril and quinaprilat were studied in male Sprague-Dawley rats using an in vivo micropunctu …
Determination of quinapril and quinaprilat by high-performance liquid chromatography with radiochemical detection, coupled to liquid scintillation counting spectrometry.
Kugler AR, Olson SC, Smith DE. Kugler AR, et al. J Chromatogr B Biomed Appl. 1995 Apr 21;666(2):360-7. doi: 10.1016/0378-4347(94)00588-v. J Chromatogr B Biomed Appl. 1995. PMID: 7633615
Perfusate ultrafiltrate was used as collected. Two quinapril diketopiperazine metabolites, PD 109488 and PD 113413, were separated chromatographically from quinapril, quinaprilat, and from each other. Assay performance for quinapril and quinaprilat was …
Perfusate ultrafiltrate was used as collected. Two quinapril diketopiperazine metabolites, PD 109488 and PD 113413, were separ …
123 results